These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 27286893)

  • 1. Intravitreal aflibercept for myopic choroidal neovascularization.
    Pece A; Milani P
    Graefes Arch Clin Exp Ophthalmol; 2016 Dec; 254(12):2327-2332. PubMed ID: 27286893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
    Yang HS; Kim JG; Kim JT; Joe SG
    Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.
    Ikuno Y; Ohno-Matsui K; Wong TY; Korobelnik JF; Vitti R; Li T; Stemper B; Asmus F; Zeitz O; Ishibashi T;
    Ophthalmology; 2015 Jun; 122(6):1220-7. PubMed ID: 25745875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
    Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
    Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
    Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fundus Autofluorescence Changes After Ranibizumab Treatment for Subfoveal Choroidal Neovascularization Secondary to Pathologic Myopia.
    Parodi MB; Iacono P; Sacconi R; Iuliano L; Bandello F
    Am J Ophthalmol; 2015 Aug; 160(2):322-327.e2. PubMed ID: 25935099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy.
    Jeong S; Sagong M
    Br J Ophthalmol; 2017 Jun; 101(6):758-763. PubMed ID: 27597740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Ng DS; Kwok AK; Tong JM; Chan CW; Li WW
    Retina; 2015 Dec; 35(12):2457-68. PubMed ID: 26035400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors for intravitreal conbercept in the treatment of choroidal neovascularization secondary to pathological myopia.
    Wang D; Wu K; Li X; Chen L; Huang W
    Int Ophthalmol; 2024 Jun; 44(1):253. PubMed ID: 38907787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.
    Ruiz-Moreno JM; Arias L; Montero JA; Carneiro A; Silva R
    Br J Ophthalmol; 2013 Nov; 97(11):1447-50. PubMed ID: 24026146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study.
    Gliem M; Birtel J; Herrmann P; Fimmers R; Berger M; Coch C; Wingen A; Holz FG; Charbel Issa P
    Graefes Arch Clin Exp Ophthalmol; 2020 Feb; 258(2):311-318. PubMed ID: 31863395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Result of intravitreal aflibercept injection for myopic choroidal neovascularization.
    Chen SL; Tang PL; Wu TT
    BMC Ophthalmol; 2021 Sep; 21(1):342. PubMed ID: 34551746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study.
    Bruè C; Pazzaglia A; Mariotti C; Reibaldi M; Giovannini A
    Eye (Lond); 2016 Jan; 30(1):139-45. PubMed ID: 26514244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration.
    Braimah IZ; Stewart M; Videkar C; Dedhia CJ; Chhablani J;
    Br J Ophthalmol; 2017 Sep; 101(9):1201-1205. PubMed ID: 28119292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks.
    Esen E; Sizmaz S; Demircan N
    Indian J Ophthalmol; 2015 Jul; 63(7):616-8. PubMed ID: 26458482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM; Lai TY; Liu DT; Lam DS
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS
    Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.
    Cohen SY; Nghiem-Buffet S; Grenet T; Dubois L; Ayrault S; Fajnkuchen F; Delahaye-Mazza C; Quentel G; Tadayoni R
    Jpn J Ophthalmol; 2015 Jan; 59(1):36-42. PubMed ID: 25416566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
    Ahn SJ; Park KH; Woo SJ
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization.
    Wang JK; Huang TL; Chang PY; Chen YT; Chang CW; Chen FT; Hsu YR; Chen YJ
    Sci Rep; 2018 Sep; 8(1):14389. PubMed ID: 30258077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.